Severity of COVID-19: The importance of being hypertensive

Fabio Angeli1,2, Sergio Masnaghetti1,2, Dina Visca1,2, Alessandra Rossoni1,2, Sara Taddeo1,2, Filippo Biagini1,2, Paolo Verdecchia3

1Department of Medicine and Surgery, University of Insubria, Varese; 2Department of Medicine and Cardiopulmonary Rehabilitation, Maugeri Care and Research Institute, IRCCS Tradate, Varese; 3Fondazione Umbra Cuore e Ipertensione ONLUS and Division of Cardiology, Hospital S. Maria della Misericordia, Perugia, Italy

The novel respiratory Syndrome Coronavirus-2 (SARS-CoV-2) caused a cluster of pneumonia cases in China at the end of 2019. After few months, it led to a pandemic that has spread throughout most countries of the world (https://coronavirus.jhu.edu/map.html). SARS-CoV-2 disease (COVID-19) primarily manifests as a lung infection and its clinical course is characterized by respiratory symptoms ranging from a mild respiratory infection (including fever, cough and fatigue) to pneumonia, acute respiratory distress syndrome (ARDS), shock, and death [1]. Among the proposed mechanisms of injury caused by SARS-CoV-2, there is a “cytokine storm” triggered by an imbalanced response by type 1 and type 2 T helper cells [2]. Furthermore, an emerging body of evidence suggests that COVID-19 may predispose patients to arterial and venous thrombotic disease [3]. Fibrin deposits are found in the lungs possibly due to the dysregulation of the coagulation and fibrinolytic systems: tissue factor is exposed on damaged alveolar endothelial cells promoting fibrin deposition, while significantly elevated levels of plasminogen activator inhibitor 1 (PAI-1) from lung epithelium and endothelial cells create a hypofibrinolytic state [3].

Numerous clinical studies showed that COVID-19 disproportionately affects patients with pre-existing comorbidities. According to a meta-analysis of 7 studies including 1576 laboratory-confirmed COVID-19 infected patients, the most prevalent comorbidity was hypertension [4]. Furthermore, patients with hypertension appear to be at increased risk from COVID-19 infection. More specifically, a pooled analysis of 13 studies, with a total of 2893 patients with COVID-19 documented that hypertension was associated with a 2.5-fold increased risk of severe COVID-19 (odds ratio [OR]: 2.49; 95% confidence interval [CI]: 1.98-3.12; \( I^2 = 24\% \)) and a higher risk of mortality (OR: 2.42; 95% CI: 1.51-3.90; \( I^2 = 0\% \)) [5].

Taken together, these findings suggest that hypertension is linked to the pathogenesis of COVID-19. In this regard, the renin-angiotensin-aldosterone-system (RAAS) plays an important role in the pathogenesis of hypertension and the pathways involved in the generation of angiotensin II (Ang II) and Angiotensin1,7 (Ang1,7) have been recently recognized as potential markers of COVID-19 severity. Angiotensin converting enzyme-2 (ACE2) receptors are involved in the degradation of Ang II to Ang1,7, but they also mediate the entry into the cell of SARS-CoV-2. Of note, Ang1,7 opposes the deleterious effects of Ang II, including vasoconstriction, proliferative, profibrotic and proinflammatory effects, and prothrombotic actions. The entry of SARS-CoV-2 into the cells through membrane fusion markedly down-regulates ACE2 receptors, with loss of the catalytic effect of these receptors at the external site of the membrane. Thus, this phenomenon translates in an increased state of pulmonary inflammation and coagulation (Figure 1).

It has been noted that hypertension may be associated with a variable degree of ACE2 deficiency [6,7]. In this setting, ACE2 down-regulation induced by SARS-CoV-2 has the potential to be detrimental in hypertensive patients through a further worsening of the imbalance between Ang II and Ang1,7 [6,7]. Such dysregulation would markedly decrease the activity of Ang1,7, thereby rendering the lungs more susceptible to the detrimental actions of Ang II (Figure 1). In other words, the progression of inflammatory and thrombotic processes may be triggered by Ang II hyperactivity unopposed by Ang1,7 [6].

Paraphrasing an aphorism of Oscar Wilde (from “The importance of being Earnest”, 1895), we could state that “the truth is rarely pure and never simple”. This appears particularly true for the complex mechanisms linking COVID-19 with hypertension. The theorized physiopathological imbalance between Ang II and Ang1,7 might play a central role in explaining many clinical features of COVID-19. Notably, it also provides a solid rationale to investigate the impact of some therapeutic measures which include the use of Ang II type 1 receptor blockers, soluble recombinant ACE2 and Ang1,7 [6,7].

Correspondence: Prof. Fabio Angeli, Department of Medicine and Surgery, University of Insubria, Varese and Department of Medicine and Cardiopulmonary Rehabilitation, ICS Maugeri IRCCS, Institute of Tradate, Via Crotto Roncaccio 16, Tradate (VA), Italy.
Tel. +39.0331.829630 - Fax: +39.0331.829400.
E-mail: angeli.internet@gmail.com

Contributions: All authors have contributed equally to the manuscript. All authors gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Conflict of interest: the authors declare no conflict of interest.

Key words: COVID-19; SARS-CoV-2; hypertension; prognosis; angiotensin; ACE2

Received for publication: 11 May 2020.
Accepted for publication: 13 May 2020.

(C)opyright: the Author(s), 2020
Licensee PAGEPress, Italy
Monaldi Archives for Chest Disease 2020; 90:1372

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
References


Figure 1. Lung damage during COVID-19. Detrimental effects of ACE2 down-regulation induced by viral entry in a setting of pre-existing ACE2 deficiency (see text for details). ACE2 are mainly expressed in pneumocytes type II, which are responsible for the production of alveolar surfactant, and have the function of 'stem' cells, progenitors of pneumocytes type I (responsible of gas exchanges). AII, angiotensin II; A1,7, angiotensin1,7; ACE2, angiotensin converting enzyme-2.